Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

This podcast contains general information for educational purposes only. This is not professional

advice and should not be used in lieu of obtaining advice from a qualified health care provider.

And now on to the show.

Welcome to Helix Talk, episode 97. I'm your co-host, Dr. Kane. And I'm Dr. Patel. And to our listeners, we have a sad news.

Dr. Michael Schumann has departed the university and moved on to other opportunities in Kentucky.

So he won't be a regular contributor.

However, you will hear his voice, we promise, as guest speaker because he's very much interested in talking to our listeners.

Moving forward today talking about the title, Asprey, arrive, ascend, making an acronym soup for aspirin.

And Dr. Patel, it sounds like today we're talking about the use of aspirin for primary prevention,

specifically focusing on some newer literature out there.

Yeah, it's been quite a bit of undertaking on understanding whether there is good evidence

for aspirin in primary prevention.

We know that there is clear benefit in secondary prevention, but the position on primary

prevention has been tipping, and that's through

a lot of different literature that's been out. And the three acronyms that you mentioned, Dr.

Kane, they were randomized controlled trials published last year that actually compelled some of the

governing organizations like AJA and ACC to update their recommendation. So

in a nutshell, that's what we're going to discuss today. And just for complete clarity, when we say

primary prevention, that means using aspirin, someone who's never had a heart attack or a stroke,

versus secondary prevention and someone who has had a heart attack in the stroke and are trying

...